Kilari, D., Ballman, K. V., Gelmann, E. P., Zarrabi, K. K., Baghaie, S., Sumey, C. J., Hillman, D. W., Bryce, A. H., Rose, B. S., Nguyen, P., Montgomery, R. B., Berg, S. A., Tan, A., Jacene, H., Chen, R. C., Beltran, H., Morris, M. J., Galsky, M. D., Rosenberg, J. E., McKay, R. R. (2026). ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps290